v3.26.1
Consolidated Statements of Operations (Unaudited) - USD ($)
 3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Revenue:    
Total revenue $ 1,110,956 $ 393,572
Costs and expenses:    
Cost of research and development revenue 340,157 126,480
Cost of grant revenue 451,683 171,178
Research and development 476,069 494,979
General and administrative 1,755,331 1,596,338
Foreign currency exchange (gain) loss (9,591) 7,072
Total costs and expenses 3,013,649 2,396,047
Loss from operations (1,902,693) (2,002,475)
Other income (expense):    
Interest income 57,191 88,458
Total other income (expense), net (51,990) (25,104)
Net loss $ (1,954,683) $ (2,027,579)
Basic net loss per common share $ (0.05) $ (0.07)
Diluted net loss per common share $ (0.05) $ (0.07)
Basic weighted-average common shares outstanding 36,397,997 29,886,665
Diluted weighted-average common shares outstanding 36,397,997 29,886,665
Nonrelated Party [Member]    
Other income (expense):    
Interest expense $ (64,342) $ (89,243)
Related Party [Member]    
Other income (expense):    
Interest expense (44,839) (24,319)
Research And Development Expenses [Member]    
Revenue:    
Total revenue 403,590 183,100
Grant [Member]    
Revenue:    
Total revenue 487,366 210,472
License [Member]    
Revenue:    
Total revenue $ 220,000